Zydus Cadila has received final approval from the US health regulator to market Memantine Hydrochloride tablets, used to treat dementia, in America, its listed entity Cadila Healthcare said today.
The company will manufacture the drug at its plant in Moraiya, Ahmedabad.
It has more than 120 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
The stock was trading 0.07 per cent down at Rs 517.15 apiece on BSE today.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)